|
WO2020249507A1
|
|
Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
|
|
WO2020212256A1
|
|
Diasteroselective process for the preparation of thiol- or disulfide-containing maytansinoid esters and intermediates thereof
|
|
WO2020212190A1
|
|
Method and kit for the identification of vaccinium myrtillus
|
|
AU2019311840A1
|
|
Compositions comprising an American cranberry extract and phospholipids
|
|
IT201900003907A1
|
|
COMPOSITIONS INCLUDING CURCUMIN AND COENZYME Q10
|
|
WO2019162382A1
|
|
Cosmetic compositions for protection against light-induced damages
|
|
US2020368215A1
|
|
Compositions comprising berberine
|
|
EP3653596A1
|
|
Continuous flow synthesis of cannabidiol
|
|
EP3620453A1
|
|
New crystal form of lenvatinib
|
|
EP3620452A1
|
|
Process for the preparation of lenvatinib
|
|
CA3069055A1
|
|
Powder solid dispersions comprising quercetin, process for their preparation and formulations thereof
|
|
WO2018189100A1
|
|
Compositions comprising essential oils
|
|
EP3609516A1
|
|
Compositions comprising essential oils for topical use
|
|
WO2018069323A1
|
|
Extracts and combinations thereof for use as yeasts and fungi inhibitors
|
|
WO2018046337A1
|
|
Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same
|
|
AU2017288470A1
|
|
Compositions useful in the prevention and/or treatment of osteoarticular inflammation and pain and cartilage damage
|
|
CN108778304A
|
|
For preventing and/or treating oral cavity, the upper respiratory tract and the composition of esophagus disease
|
|
EP3419641A1
|
|
Compositions useful in the prevention and/or treatment of inflammation and pain
|
|
EP3335716A1
|
|
Process for the preparation of powder compositions
|
|
EP3332768A1
|
|
Powder solid compositions comprising flavonoids, process for their preparation, formulations and use thereof
|
